Kommentar

• Literatur

• 1 Choueiri TK, Tomczak P, Park SH. et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med 2024; 390: 1359-1371
• 2 Allaf ME, Kim SE, Master V. et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25: 1038-1052
• 3 Pal SK, Uzzo R, Karam JA. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet 2022; 400: 1103-1116
• 4 Motzer RJ, Russo P, Grünwald V. et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. The Lancet 2023; 401: 821-832
• 5 Choueiri TK, Tomczak P, Park SH. et al. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564. JCO 2022; 40 (Suppl. 16) 4512-4512
• 6 Powles T, Burotto M, Escudier B. et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open 2024; 9: 102994
• 7 Motzer RJ, Porta C, Eto M. et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JCO 2024; 42: 1222-1228